Skip To Main Content

Search

For optimal search results, please limit to 2 product keywords

If you are searching for information related to a product:

  • For optimal results, please enter at least 2 search terms in addition to product name
  • Example: [product name] [search term] [search term]
  • Example: Product + clinical trials
  • For an exact match, please include search terms in double quotations. For example: "Elevatum"

    Please enter search terms.

    Neuroscience

    Neuroimmunological Disease
    Neuromuscular Disease
    Neurodegenerative Disease

    For optimal search results, please limit to 2 product keywords

    If you are searching for information related to a product:

    • For optimal results, please enter at least 2 search terms in addition to product name
    • Example: [product name] [search term] [search term]
    • Example: Product + clinical trials
    • For an exact match, please include search terms in double quotations. For example: "Elevatum"

      Please enter search terms.

      AAN 2026

      American Academy of Neurology (AAN)

      April 18-22

      Chicago, Illinois

      Browse agenda

      Jump to section:

      Presentations & Posters at AAN 2026
      Pipeline
      Mechanism of Action
      Actively Recruiting Clinical Trials
      Additional Resources

      Genentech Presentations & Posters at AAN 2026

      The list of conference materials is a subset of Roche/Genentech posters and oral presentations for the products that have data presented at the AAN 2026 conference. To browse full Roche/Genentech congress presentations and posters: Visit Medically.

      Links to these presentations and posters will be added after the conference.

      Presentation

      Preservation of Ambulation and Hand Function at Healthy-Control Levels With First-Line Treatment With Ocrelizumab: 6-Year Findings From the ENSEMBLE Trial

      Oral 003

      View Presentation
      Presentation

      Humoral Vaccine Responses and 1-Year Follow-Up of Infants Potentially Exposed to Ocrelizumab During Pregnancy and Breastfeeding: Final Analyses of the Prospective, Multicenter, Open-Label, Phase IV Studies MINORE and SOPRANINO

      Oral 002

      View Presentation
      Poster

      Week 96 Analysis of the OCARINA II Study Characterizing Subcutaneous Ocrelizumab in Patients With Relapsing or Primary Progressive Multiple Sclerosis

      Poster 006

      View Poster
      Presentation

      ORATORIO-HAND: Results of the Primary Analysis of Ocrelizumab vs Placebo in Primary Progressive Multiple Sclerosis, Including Older Patients and Those With More Advanced Disease

      Oral 001

      View Presentation
      Presentation

      Efficacy and Safety of Ocrelizumab Compared With Fingolimod in Pediatric-Onset Relapsing-Remitting MS: Results of the Phase III OPERETTA 2 Study

      Oral 005

      View Presentation
      Presentation

      Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study

      Oral 004

      View Presentation
      Poster

      Outsmarting Therapeutic Inertia: Can ChatGPT-4o Beat Neurologists in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder Care?

      Monday, April 20, at 5:00-6:00 PM CT

      View Poster
      Poster

      Patients' Knowledge and Attitudes Toward Serum Neurofilament Light Chain Testing in Early-stage Relapsing-remitting Multiple Sclerosis

      Monday, April 20, at 11:45-12:45  PM CT

      View Poster
      Presentation

      Efficacy and Safety of Fenebrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Results of the FENhance 1 and 2 Studies

      Oral and Poster 005

      View Presentation
      Poster

      Real-world Motor Function Outcomes with Risdiplam in Types 2 and 3 Spinal Muscular Atrophy (SMA): A Systematic Literature Review and Meta-analysis

      Monday, April 20, from 11:45 AM–12:45 PM CT

      View Poster
      Poster

      Beyond Motor Function in Adults with Spinal Muscular Atrophy (SMA): A Systematic Literature Review of Real-world Outcomes with Risdiplam

      Monday, April 20, from 11:45 AM–12:45 PM CT

      View Poster
      Presentation

      Safety and efficacy of satralizumab in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Results from the phase 3 METEOROID trial

      Tuesday, April 21, 2026, from 9:15 a.m. to 11:30 a.m. CT [Clinical Trials Plenary Session]

      View Presentation

      Pipeline

      Genentech’s pipeline for Neuroscience includes multiple molecules currently under investigation.

      These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

      USM 2026 AAN Animated Pipeline

      Mechanism of Action

      Neuroimmunological Disease

      Multiple Sclerosis Pathophysiology and role of BTK

      Exploring the pathophysiology of MS and the pivotal role of BTK in chronic central nervous system inflammation.

      View Video
      Neurodegenerative Disease

      Brainshuttle™: Overcoming the Blood-Brain Barrier

      An introduction to Brainshuttle™ technology, an innovative platform that utilizes transferrin receptors to transport large therapeutic molecules across the blood-brain barrier.

      View Video

      Actively Recruiting Clinical Trials

      These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

      Neuroimmunological Disease

      Ocrelizumab
      Indication Phase Trial Name
      Multiple Sclerosis Phase II A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) (PORTAMENTO) Visit trial
      Fenebrutinib
      Indication Phase Trial Name
      Multiple Sclerosis Phase II A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS) (FENerations1) Visit trial
      RO7121932
      Indication Phase Trial Name
      Multiple Sclerosis Phase I A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 in Participants With Multiple Sclerosis (B-Shuttle) Visit trial
      P-CD19CD20-ALLO1
      Indication Phase Trial Name
      Multiple Sclerosis Phase I A Phase I, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Patients With Multiple Sclerosis Visit trial
      Satralizumab
      Indication Phase Trial Name
      Autoimmune Encephalitis Phase III A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis (Cielo) Visit trial
      NMOSD Phase III A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) (SAkuraSun) Visit trial
      MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY DISEASE Phase III A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (Meteoroid) Visit trial

      Neuromuscular Disease

      Risdiplam
      Indication Phase Trial Name
      SMA Phase II A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy (PUPFISH) Visit trial
      SMA Phase IV A Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Patients With Spinal Muscular Atrophy After Gene Therapy (HINALEA 1) Visit trial
      SMA Phase IV A Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy (HINALEA 2) Visit trial
      SMA Phase IV An observational study to look at the effects of Evrysdi (risdiplam) on fertility in adult male with spinal muscular atrophy (MARLIN) Visit trial

      Neurodegenerative Disease

      Prasinezumab
      Indication Phase Trial Name
      Parkinson's disease Phase III A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease (PARAISO) Visit trial
      Trontinemab
      Indication Phase Trial Name
      Alzheimer's Phase III A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (TRONTIER I) Visit trial
      Alzheimer's Phase III A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (TRONTIER II) Visit trial
      Alzheimer's Phase III Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition (TRAVELLER) Visit trial

      Interested in becoming an investigator or have trial questions?

      Reach out to an MSL

      Additional Resources

      Neurodegenerative Disease

      The Alzheimer's Disease Diagnostic Pathway

      Streamlining the Alzheimer’s diagnostic pathway: The role of biomarkers in ensuring accurate diagnosis and improving access to treatment.

      View Video
      Neurodegenerative Disease

      Parkinson's Disease Clinical Trial Brochure - PARAISO

      This brochure details the PARAISO Phase III clinical trial, a study sponsored by Roche to evaluate the efficacy and safety of intravenous Prasinezumab in patients with early-stage Parkinson's disease

      View Brochure

      Looking for more information?

      Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.

      Connect with an MSL
      Submit a Request

      Call Us: 1-800-821-8590 Hours: Monday-Friday, 5am-5pm PT

      TOP
      +